Do you want to read an article? Please log in or register.
Does robotic segmentectomy improve long-term outcomes in non-small cell lung cancer?
Further Publications
RECOMMENDED
Related content
Lung Cancer
10-Year Long-Term Outcomes of Robotic-Assisted Segmentectomy for Early-Stage Non-Small-Cell Lung Cancer
J Clin Med
Casiraghi M, Orlandi R, Mazzella A, Girelli L, Caffarena G, Chiari M, Bertolaccini L, Lo Iacono G, Diotti C, Bardoni C, Maisonneuve P, Spaggiari L
doi: 10.3390/jcm14165608
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Lung Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung Cancer
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer
J Thorac Oncol
Torasawa M, Masui Y, Miura K, Kataoka S, Shirasawa M, Nakahara Y, Baba J, Ishii H, Asai M, Aiba T, Wakui H, Sugawara S, Hosomi Y, Tanaka H, Naoki K, Takahashi K, Kenmotsu H, Horinouchi H
doi: 10.1016/j.jtho.2026.104113
COMMENTED
Lung Cancer
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
JAMA Oncol
Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B
doi: 10.1001/jamaoncol.2026.0669
Lung Cancer
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution
Eur J Cancer
Corre R, Monnet I, Moreau L, Pinsolle J, Hominal S, Campana M, Chikouche R, Slaouti P, Tavernier JY, Clarot C, Kuntz P, Fouet K, Rabut H, Dehette S, Thirard L, Paysse M, Nunes D, Letierce A, Morel H, Debieuvre D, Study Group KBP-2020-CPHG
doi: 10.1016/j.ejca.2026.116845
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer
Clin Lung Cancer
Pham D, Thakur N, Park JA, Nie W, Correa M, Wang H, Subramanian M, Weyant M, Johnson CB, Suzuki K
doi: 10.1016/j.cllc.2025.10.008
Lung Cancer
A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution
Clin Lung Cancer
Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M
doi: 10.1016/j.cllc.2025.09.003